Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Advances in Respiratory Medicine
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Author statement Editorial Policy and Information for Authors

open access

Vol 77, No 1 (2009)
REVIEWS
Published online: 2008-12-19
Submitted: 2013-02-22
View PDF (polish) Download PDF file
Get Citation

Tuberculosis after renal transplantation

Anna Korzeniewska, Tomasz Dyła, Monika Kosacka, Renata Jankowska
Pneumonol Alergol Pol 2009;77(1):61-65.

open access

Vol 77, No 1 (2009)
REVIEWS
Published online: 2008-12-19
Submitted: 2013-02-22

Abstract

Renal transplant recipients carry a relatively high risk of developing tuberculosis (TB). In most cases, active TB is the result of reactivation of a latent infection and is located in the lungs. In these patients, clinical presentation of TB can often be atypical and there is a high risk of dissemination and high mortality rates. Therefore, the use of invasive procedures for proper diagnosis is recommended, as well as anti-tuberculosis therapy instituted whenever there is a strong suspicion of TB on clinical grounds, even without microbiological evidence. The treatment of active TB in renal transplant recipients should be the same as in the general population. To avoid graft rejection, blood levels of calcineurin inhibitors should be monitored closely. Prophylaxis is recommended for high-risk patients.

Abstract

Renal transplant recipients carry a relatively high risk of developing tuberculosis (TB). In most cases, active TB is the result of reactivation of a latent infection and is located in the lungs. In these patients, clinical presentation of TB can often be atypical and there is a high risk of dissemination and high mortality rates. Therefore, the use of invasive procedures for proper diagnosis is recommended, as well as anti-tuberculosis therapy instituted whenever there is a strong suspicion of TB on clinical grounds, even without microbiological evidence. The treatment of active TB in renal transplant recipients should be the same as in the general population. To avoid graft rejection, blood levels of calcineurin inhibitors should be monitored closely. Prophylaxis is recommended for high-risk patients.

Full Text:

View PDF (polish) Download PDF file
Get Citation

Keywords

tuberculosis; renal transplantation; immunosuppression

About this article
Title

Tuberculosis after renal transplantation

Journal

Advances in Respiratory Medicine

Issue

Vol 77, No 1 (2009)

Pages

61-65

Published online

2008-12-19

Bibliographic record

Pneumonol Alergol Pol 2009;77(1):61-65.

Keywords

tuberculosis
renal transplantation
immunosuppression

Authors

Anna Korzeniewska
Tomasz Dyła
Monika Kosacka
Renata Jankowska

References (38)
  1. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998; 27(5): 1266–1277.
    PubMed
  2. Vandermarliere A, Van Audenhove A, Peetermans WE, et al. Mycobacterial infection after renal transplantation in a Western population. Transpl Infect Dis. 2003; 5(1): 9–15.
    PubMed
  3. Lezaic V, Radivojevic R, Radosavljevic G, et al. Does tuberculosis after kidney transplantation follow the trend of tuberculosis in general population? Ren Fail. 2001; 23(1): 97–106.
    PubMed
  4. European best practice guidlines for renal transplantation. Section : Long-term management of the transplant recipient. IV 7 2 Late infections Tuberculosis Nephrol Dial Transplant. 2002; 17: 39–43.
  5. Sayiner A, Ece T, Duman S, et al. Tuberculosis in renal transplant recipients. Transplantation. 1999; 68(9): 1268–1271.
    PubMed
  6. Queipo JA, Broseta E, Santos M, et al. Mycobacterial infection in a series of 1261 renal transplant recipients. Clin Microbiol Infect. 2003; 9(6): 518–525.
    PubMed
  7. Jereb JA, Burwen DR, Dooley SW, et al. Nosocomial Outbreak of Tuberculosis in a Renal Transplant Unit: Application of a New Technique for Restriction Fragment Length Polymorphism Analysis of Mycobacterium tuberculosis Isolates. Journal of Infectious Diseases. 1993; 168(5): 1219–1224.
    CrossRef
  8. Peters TG, Reiter CG, Boswell RL. Transmission of tuberculosis by kidney transplantation. Transplantation. 1984; 38(5): 514–516.
    PubMed
  9. Durlik M, Klinger M, Lao M, Więcek A, Rowiński W. Zalecenia dotyczące leczenia immunosupresyjnego po przeszczepieniu narządów unaczynionych. In: Rowiński W, Durlik M. ed. Fundacja Zjednoczeni dla Transplantacji. , Warszawa 2006: 13–47.
  10. Chen CH, Lian JD, Cheng CH, et al. Mycobacterium tuberculosis infection following renal transplantation in Taiwan. Transpl Infect Dis. 2006; 8(3): 148–156.
    CrossRefPubMed
  11. Higgins RM, Cahn AP, Porter D, et al. Mycobacterial infections after renal transplantation. Q J Med. 1991; 78(286): 145–153.
    PubMed
  12. Kircher B, Lätzer K, Gastl G, et al. Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies. Clin Exp Immunol. 2003; 134(3): 426–430.
    PubMed
  13. Van Gelder T, Warlé M, Ter Meulen RG. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice? Drugs. 2004; 64(16): 1737–1741.
    PubMed
  14. Qunibi WY, al-Sibai MB, Taher S, et al. Mycobacterial infection after renal transplantation--report of 14 cases and review of the literature. Q J Med. 1990; 77(282): 1039–1060.
    PubMed
  15. Drobniewski FA, Ferguson J. Tuberculosis in renal transplant units. Nephrol Dial Transplant. 1996; 11(5): 768–770.
    PubMed
  16. Rowińska D, Durlik M, Gradowska L, et al. Gruźlica u chorych po przeszczepieniu nerki. Pneumonol Alergol Pol. 1994; 62: 272–279.
  17. Apaydin S, Altiparmak MR, Serdengeçti K, et al. Mycobacterium tuberculosis infections after renal transplantation. Scand J Infect Dis. 2000; 32(5): 501–505.
    PubMed
  18. Hall CM, Willcox PA, Swanepoel CR, et al. Mycobacterial infection in renal transplant recipients. Chest. 1994; 106(2): 435–439.
    PubMed
  19. Chou KJ, Fang HC, Bai KJ, et al. Tuberculosis in maintenance dialysis patients. Nephron. 2001; 88(2): 138–143.
    CrossRefPubMed
  20. Fang HC, Lee PT, Chen CL, et al. Tuberculosis in patients with end-stage renal disease. Int J Tuberc Lung Dis. 2004; 8(1): 92–97.
    PubMed
  21. Petrie JJ, Rigby RJ, Hawley CM, et al. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation. 1988; 45(1): 68–73.
    PubMed
  22. Green M, Avery RK. Mycobacterium tuberculosis. American Journal of Transplantation. 2004; 4: 37–41.
    CrossRef
  23. Rowińska-Zakrzewska E, Kuś J. Choroby układu oddechowego. Wydawnictwo PZWL, Warszawa 2004: 548–551.
  24. Cassidy MJ, Van Zyl-Smit R, Pascoe MD, et al. Effect of rifampicin on cyclosporin A blood levels in a renal transplant recipient. Nephron. 1985; 41(2): 207–208.
    PubMed
  25. Buffington GA, Dominguez JH, Piering WF, et al. Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. JAMA. 1976; 236(17): 1958–1960.
    PubMed
  26. Aguado JM, Herrero JA, Gavaldá J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation. 1997; 63(9): 1278–1286.
    PubMed
  27. López-Montes A, Gallego E, López E, et al. Treatment of tuberculosis with rifabutin in a renal transplant recipient. Am J Kidney Dis. 2004; 44(4): e59–e63.
    PubMed
  28. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999; 281(11): 1014–1018.
    PubMed
  29. Periera BJ, Wright TL, Schmid CH, et al. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation. 1995; 60(8): 799–805.
    PubMed
  30. Genescà J, Vila J, Córdoba J, et al. Hepatitis C virus infection in renal transplant recipients: epidemiology, clinical impact, serological confirmation and viral replication. J Hepatol. 1995; 22(3): 272–277.
    PubMed
  31. John GT, Shankar V, Abraham AM, et al. Risk factors for post-transplant tuberculosis. Kidney Int. 2001; 60(3): 1148–1153.
    CrossRefPubMed
  32. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982; 60(4): 555–564.
    PubMed
  33. Pape JW, Jean SS, Ho JL, et al. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993; 342(8866): 268–272.
    PubMed
  34. Whalen C, Johnson J, Okwera A, et al. A Trial of Three Regimens to Prevent Tuberculosis in Ugandan Adults Infected with the Human Immunodeficiency Virus. New England Journal of Medicine. 1997; 337(12): 801–808.
    CrossRef
  35. Agarwal SK, Gupta S, Dash SC, et al. Prospective randomised trial of isoniazid prophylaxis in renal transplant recipient. Int Urol Nephrol. 2004; 36(3): 425–431.
    PubMed
  36. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society, MMWR. 2000; 49: 1–51.
  37. Rowińska-Zakrzewska E. Gruźlica w praktyce lekarskiej. Wydawnictwo PZWL, Warszawa 2000: 242–245.
  38. Kobashi Y, Mouri K, Obase Y, et al. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients. Eur Respir J. 2007; 30(5): 945–950.
    CrossRefPubMed

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl